ClinicalTrials.gg
CompletedNCT01315275LUDICUpdated Feb 23, 2017

A Clinical Study in Current Medical Practice of the Efficacy and Safety of Ranibizumab 0.5mg in Diabetic Patients Presenting a Visual Impairment Due to Macular Edema

A Phase 4 interventional study of Ranibizumab in Visual Impairment and Macular Edema, sponsored by Novartis Pharmaceuticals. Completed at 43 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-02-23.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
394
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing ranibizumab in Vision Disorders — none open to participants now, none under way, none of them phase 3. Ranibizumab · Vision Disorders.

Enrollment
2nd of 26
394 · median 178
Started
2011
with 3 others
Phase 4
7 of 26
none open now
Registered
7th of 26
by date
Lead sponsor
20 of 26
Novartis Pharmaceuticals

Among the 26 studies testing ranibizumab in Vision Disorders, this one is the 2nd largest by enrollment, is one of 4 that started in 2011, is one of 7 in phase 4, and was the 7th registered.

Vision Disorders

361 studies on the registry are indexed under Vision Disorders; 85 are open to participants now.

Browse Vision Disorders studies →

Open to participants now

None of the 26 studies testing ranibizumab in Vision Disorders is open now. The open studies under Vision Disorders, anywhere →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 46 Vision Disorders studies recruiting now, 21 (46%) set no upper age limit and 16 (35%) stop at 75 or younger; 18 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 26 studies testing ranibizumab in Vision Disorders as a file.
02

Study summary

The purpose of this study is to evaluate the proportion of patients with a 10 letters gain on Best Corrected Visual Acuity (BCVA) at 6 months in current medical practice.

03

Conditions studied

  • Visual Impairment
  • Macular Edema

Keywords

  • visual impairment
  • macular edema
  • ranibizumab
  • visual impairment due to macular edema
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients >18 years of age who have signed an
  • Patients with Type 1 or Type 2 diabetes mellitus (according to ADA or WHO guidelines) with not more than 10.0% at screening (Visit 1). Patients should be on diet, exercise, and/or pharmacological treatment for diabetes.
  • Patients with visual impairment due to focal or diffuse DME in at least one eye
  • Central Retinal thickness on OCT ≥ 250 microns in the central subfield
  • BCVA score between 78 and 39 letters, inclusively, using ETDRS-like visual acuity testing charts at a testing distance of 4 meters (approximate Snellen equivalent of 20/32 to 20/160)
  • Decrease in vision is due to DME and not due to other causes, in the opinion of the investigator
  • Medication for the management of diabetes must have been stable within 3 months prior to randomization and is expected to remain stable during the course of the study.

Exclusion criteria

Exclusion Criteria:

Ocular concomitant conditions/ diseases

  • Concomitant conditions in the study eye which could, in the opinion of the investigator, prevent the improvement of visual acuity on study treatment
  • Active intraocular inflammation (grade trace or above) in either eye
  • Any active infection (e.g. conjunctivitis, keratitis, scleritis, uveitis, endophthalmitis) in either eye
  • History of uveitis in either eye Systemic conditions or treatments
  • Active systemic infection
  • History of stroke \< 3 months
  • Renal failure requiring dialysis or renal transplant OR renal insufficiency with creatinine levels > 2.0 mg/dl
  • Untreated diabetes mellitus
  • Blood pressure systolic > 160 mmHg and diastolic > 100 mmHg
  • Untreated hypertension
  • Known to ranibizumab or any component of the ranibizumab formulation Others
  • Women of not using the method(s) specified in this study (specify), as well as women who are breastfeeding

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
394 participants (actual)

Study arms

  • Experimental
    Ranibizumab

    Drug: Ranibizumab

Interventions

06

What researchers measure

Primary outcomes

  1. proportion of patients with a 10 letters gain on Best Corrected Visual Acuity (BCVA)

    Time frame: 6 months

Secondary outcomes

  1. mean average change in BCVA from baseline

    Time frame: 6 months

  2. if the letters gain after 2 injections is predictive from the letters gain at 6 months

    Time frame: 6 months

  3. mean number of injections needed to obtain a 10 letters gain

    Time frame: 6 months

  4. mean number of injections needed to obtain a stable visual acuity for three consecutive monthly assessments

    Time frame: 6 months

  5. efficacy of ranibizumab IVT on Central Retinal Thickness (OCT)

    Time frame: 6 months

07

Study locations

43 sites
  • Novartis Investigative Site
    Amiens, 80054, France
  • Novartis Investigative Site
    Angers, 49044, France
  • Novartis Investigative Site
    Besançon cedex, 25030, France
  • Novartis Investigative Site
    Bobigny, 93009, France
  • Novartis Investigative Site
    Bordeaux, 33000, France
  • Novartis Investigative Site
    Bordeaux, 33100, France
  • Novartis Investigative Site
    Caen, 14050, France
  • Novartis Investigative Site
    Cesson Sevigne, 35510, France
  • Novartis Investigative Site
    Clermont-ferrand, 63014, France
  • Novartis Investigative Site
    Créteil, 94000, France
  • Novartis Investigative Site
    Grenoble, 38000, France
  • Novartis Investigative Site
    Lille, 59037, France
  • Novartis Investigative Site
    Lyon Cedex 04, 69317, France
  • Novartis Investigative Site
    Lyon, 69007, France
  • Novartis Investigative Site
    Lyon, 69275, France
  • Novartis Investigative Site
    Lyon, 69437, France
  • Novartis Investigative Site
    Mantes la joile, 78201, France
  • Novartis Investigative Site
    Marseille cedex 05, 13385, France
  • Novartis Investigative Site
    Marseille, 13008, France
  • Novartis Investigative Site
    Melun, 77000, France
  • Novartis Investigative Site
    Montpellier, 34000, France
  • Novartis Investigative Site
    Montpellier, 34295, France
  • Novartis Investigative Site
    Nice, 06000, France
  • Novartis Investigative Site
    Nimes, 30029, France
  • Novartis Investigative Site
    Osny, 95520, France
  • Novartis Investigative Site
    Paris Cedex 19, 75940, France
  • Novartis Investigative Site
    Paris, Cedex 12, F-75571, France
  • Novartis Investigative Site
    Paris, 75006, France
  • Novartis Investigative Site
    Paris, 75007, France
  • Novartis Investigative Site
    Paris, 75015, France
  • Novartis Investigative Site
    Puilboreau, 17138, France
  • Novartis Investigative Site
    Reims, 51092, France
  • Novartis Investigative Site
    Rouen, 76100, France
  • Novartis Investigative Site
    Saint Brieuc, 22015, France
  • Novartis Investigative Site
    Saint Etienne, 42000, France
  • Novartis Investigative Site
    Saitnt Herblain, 44819, France
  • Novartis Investigative Site
    St Jean, 31240, France
  • Novartis Investigative Site
    St-Priest-en-Jarez, 42270, France
  • Novartis Investigative Site
    Strasbourg, 67000, France
  • Novartis Investigative Site
    Toulouse, 31077, France
  • Novartis Investigative Site
    Tours, 37044, France
  • Novartis Investigative Site
    Vandoeuvre les Nancy, 54511, France
  • Novartis Investigative Site
    Vannes, 56000, France
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2011, a primary completion of Aug 2012 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2011
First posted
Mar 15, 2011
Start
Feb 2011
Primary completionActual
Aug 2012
CompletionActual
Aug 2012
Last update
Feb 23, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 23, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01315275
Responsible party
Sponsor
First posted
Mar 15, 2011
Start date
Feb 2011
Primary completion
Aug 2012
Completion
Aug 2012
Last update
Feb 23, 2017

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion